NO312065B1 - Benzosulfon-derivater, anvendelse og fremgangsmåte for fremstilling derav, samt medikament - Google Patents

Benzosulfon-derivater, anvendelse og fremgangsmåte for fremstilling derav, samt medikament Download PDF

Info

Publication number
NO312065B1
NO312065B1 NO19990187A NO990187A NO312065B1 NO 312065 B1 NO312065 B1 NO 312065B1 NO 19990187 A NO19990187 A NO 19990187A NO 990187 A NO990187 A NO 990187A NO 312065 B1 NO312065 B1 NO 312065B1
Authority
NO
Norway
Prior art keywords
amino
sulfonyl
benzenesulfonyl
phenylamine
mol
Prior art date
Application number
NO19990187A
Other languages
English (en)
Norwegian (no)
Other versions
NO990187D0 (no
NO990187L (no
Inventor
Michael Boes
Walter Hunkeler
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO990187D0 publication Critical patent/NO990187D0/no
Publication of NO990187L publication Critical patent/NO990187L/no
Publication of NO312065B1 publication Critical patent/NO312065B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO19990187A 1998-01-16 1999-01-15 Benzosulfon-derivater, anvendelse og fremgangsmåte for fremstilling derav, samt medikament NO312065B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98100690 1998-01-16

Publications (3)

Publication Number Publication Date
NO990187D0 NO990187D0 (no) 1999-01-15
NO990187L NO990187L (no) 1999-07-19
NO312065B1 true NO312065B1 (no) 2002-03-11

Family

ID=8231273

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19990187A NO312065B1 (no) 1998-01-16 1999-01-15 Benzosulfon-derivater, anvendelse og fremgangsmåte for fremstilling derav, samt medikament

Country Status (33)

Country Link
US (1) US5990105A (fr)
EP (1) EP0930302B1 (fr)
JP (1) JP3249092B2 (fr)
KR (1) KR100319250B1 (fr)
CN (1) CN1148356C (fr)
AR (1) AR014313A1 (fr)
AT (1) ATE236136T1 (fr)
AU (1) AU757841B2 (fr)
BR (1) BR9900065A (fr)
CA (1) CA2258454A1 (fr)
CO (1) CO5090847A1 (fr)
CZ (1) CZ12099A3 (fr)
DE (1) DE69906397T2 (fr)
DK (1) DK0930302T3 (fr)
ES (1) ES2193607T3 (fr)
HR (1) HRP990011B1 (fr)
HU (1) HUP9900120A3 (fr)
ID (1) ID23234A (fr)
IL (1) IL128027A (fr)
MA (1) MA26599A1 (fr)
MY (1) MY121778A (fr)
NO (1) NO312065B1 (fr)
NZ (1) NZ333706A (fr)
PE (1) PE20000170A1 (fr)
PL (1) PL194735B1 (fr)
PT (1) PT930302E (fr)
RU (1) RU2201922C2 (fr)
SG (1) SG71898A1 (fr)
SI (1) SI0930302T1 (fr)
TR (1) TR199900090A3 (fr)
TW (1) TW553938B (fr)
YU (1) YU1199A (fr)
ZA (1) ZA99254B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
DE19956791A1 (de) * 1999-11-25 2001-05-31 Merck Patent Gmbh Neue Sulfonyloxazolamine
EP2298738B1 (fr) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
HRP20040090A2 (en) 2001-08-10 2004-12-31 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
MXPA04003419A (es) * 2001-10-09 2004-07-08 Upjohn Co Tetrahidro y hexahidro-carbazoles sustituidos con arilsulfonilo como ligandos del receptor 5-ht-6.
BRPI0308696B8 (pt) * 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
US7423148B2 (en) * 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
MX2007007558A (es) * 2004-12-21 2007-07-24 Hoffmann La Roche Derivados de tetralina y de indano y usos de los mismos.
EP1877381A1 (fr) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines utiles en tant que modulateurs de canaux ioniques
RU2424229C2 (ru) * 2005-10-06 2011-07-20 Астразенека Аб Производные бифенилоксиуксусной кислоты, их применение для изготовления лекарственного средства и промежуточные соединения
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2044043B2 (fr) 2006-06-16 2021-03-03 H. Lundbeck A/S 1-[2-(2, 4-dimethylphenylsulfanyl)-phenyl]piperazine hydrobromide comme compose presentant une activite sur la serotonine, 5-ht3 et 5-ht1a pour le traitement du deficit cognitif
ES2358549T3 (es) * 2006-11-09 2011-05-11 F. Hoffmann-La Roche Ag Arilsulfonil, pirrolidinas como inhibidores de 5-ht6.
WO2008098058A1 (fr) * 2007-02-06 2008-08-14 Novartis Ag Inhibiteurs de la pi3-kinase et procédés de leur utilisation
CN101835748B (zh) * 2007-10-26 2012-11-14 苏文生命科学有限公司 氨基芳基磺胺化合物及其作为5-ht6配体的用途
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
RU2443697C1 (ru) 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
HRP20180121T1 (hr) 2013-01-18 2018-02-23 Cardioxyl Pharmaceuticals Inc. Donori nitroksila s poboljšanim terapijskim indeksom
EP2970240B1 (fr) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
WO2015090233A1 (fr) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Composés hétérocycliques aromatiques et leur utilisation dans les produits pharmaceutiques
GB201514021D0 (en) * 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CA3051539A1 (fr) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Pyridines a substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47450A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Sulfinylpyridines et leur utilisation dans le traitement du cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55151560A (en) * 1979-05-14 1980-11-26 Ishihara Sangyo Kaisha Ltd Pyridylthioaniline compound
JPS60185764A (ja) * 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
EP0466096A1 (fr) * 1990-07-12 1992-01-15 Jujo Paper Co., Ltd. Dérivés de 4-hydroxyphénylsulfone
JP3262170B2 (ja) * 1990-11-27 2002-03-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ３，６―ジ置換２―ハロピリジン化合物
CA2059450A1 (fr) * 1991-01-24 1992-07-25 Nobuyuki Sakashita Compose de pyridinesulfonamide a substituant ou son sel, son procede d'obtention et herbicide qui en contient
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
JPH06127956A (ja) * 1992-10-16 1994-05-10 Copal Co Ltd ガラスレンズの成形装置
JP3907721B2 (ja) * 1995-08-23 2007-04-18 株式会社クラレ ２−アラルキルオキシピリジン類の製造法
JP3907722B2 (ja) * 1995-08-23 2007-04-18 株式会社クラレ ２−ヒドロキシピリジン類および／または２（１ｈ）−ピリドン類の製造法
EP0894791A4 (fr) * 1996-03-29 2001-07-11 Ube Industries Composes de pyrimidine, procede de production de ces composes et bactericides pour l'agriculture et l'horticulture
JP3814885B2 (ja) * 1996-09-03 2006-08-30 宇部興産株式会社 ２−シアノピリミジン誘導体、その製造法及び農園芸用の殺菌剤
US6191280B1 (en) * 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
US6197962B1 (en) * 1998-01-26 2001-03-06 Kuraray Co., Ltd. Method for producing 2-sulfonylpyridine derivatives and method for producing 2-{[(2-pyridyl)methyl]thio}-1H-benzimidazole derivatives

Also Published As

Publication number Publication date
EP0930302A3 (fr) 1999-09-01
SI0930302T1 (en) 2003-10-31
MA26599A1 (fr) 2004-12-20
ATE236136T1 (de) 2003-04-15
CA2258454A1 (fr) 1999-07-16
JP2000053635A (ja) 2000-02-22
CN1148356C (zh) 2004-05-05
SG71898A1 (en) 2000-04-18
IL128027A0 (en) 1999-11-30
NZ333706A (en) 2000-08-25
MY121778A (en) 2006-02-28
EP0930302B1 (fr) 2003-04-02
CZ12099A3 (cs) 1999-08-11
AU1211099A (en) 1999-08-05
HK1022310A1 (en) 2000-08-04
AR014313A1 (es) 2001-02-07
NO990187D0 (no) 1999-01-15
KR19990067875A (ko) 1999-08-25
HUP9900120A2 (hu) 1999-11-29
IL128027A (en) 2004-03-28
DE69906397T2 (de) 2004-02-19
PL330841A1 (en) 1999-07-19
PE20000170A1 (es) 2000-03-29
PT930302E (pt) 2003-07-31
AU757841B2 (en) 2003-03-06
ES2193607T3 (es) 2003-11-01
TR199900090A2 (xx) 1999-08-23
PL194735B1 (pl) 2007-06-29
HRP990011A2 (en) 1999-10-31
TW553938B (en) 2003-09-21
DE69906397D1 (de) 2003-05-08
YU1199A (sh) 2002-08-12
KR100319250B1 (ko) 2002-01-05
TR199900090A3 (tr) 1999-08-23
EP0930302A2 (fr) 1999-07-21
HRP990011B1 (en) 2004-12-31
HUP9900120A3 (en) 2001-02-28
ZA99254B (en) 1999-07-16
CO5090847A1 (es) 2001-10-30
NO990187L (no) 1999-07-19
RU2201922C2 (ru) 2003-04-10
CN1231287A (zh) 1999-10-13
DK0930302T3 (da) 2003-07-21
ID23234A (id) 2000-03-30
US5990105A (en) 1999-11-23
BR9900065A (pt) 2000-05-09
HU9900120D0 (en) 1999-03-29
JP3249092B2 (ja) 2002-01-21

Similar Documents

Publication Publication Date Title
NO312065B1 (no) Benzosulfon-derivater, anvendelse og fremgangsmåte for fremstilling derav, samt medikament
US5998665A (en) Use of sulfonamides
CA2559733C (fr) Inhibiteurs d&#39;histone desacetylase
AU682026B2 (en) New 4-aminopyridines, process for preparing the same and medicaments containing the same
AU673103B2 (en) Aryl and heterocyclic cyanoguanidine derivatives
CN102639503B (zh) 作为烟酰胺磷酸核糖基转移酶抑制剂的吡啶基衍生物
AU2011223790A1 (en) Compounds and therapeutic uses thereof
CA2422013A1 (fr) Antagonistes du recepteur y.y5 de neuropeptide d&#39;urease substitue
EP1651595A2 (fr) Inhibiteurs de ligase d&#39;ubiquitine
CA2786999A1 (fr) Composes et procedes
JP2010513406A (ja) 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物
PL175788B1 (pl) Amidowe pochodne indolu i zawierające je kompozycje farmaceutyczne
MX2007014263A (es) Nuevos derivados de cromano o tetrahidronaftaleno 8-sulfonil-3-aminosustituidos que modulan al receptor de 5-hidroxi-triptamina 6.
TW200540161A (en) 4-Amino-5-cyanopyrimidine derivatives
NZ585087A (en) Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CA3158288C (fr) Composes heteroaryle et leurs utilisations therapeutiques dans des conditions associees a l&#39;alteration de l&#39;activite de la beta-glucocerebrosidase
CA3158288A1 (fr) Composes heteroaryle et leurs utilisations therapeutiques dans des conditions associees a l&#39;alteration de l&#39;activite de la beta-glucocerebrosidase